Tirzepatide vs CagriSema
Compare the research profiles of Tirzepatide and CagriSema. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesTirzepatide
Tirzepatide (Mounjaro/Zepbound)
weight-loss
Phase 4 (Post-Market)
approved
CagriSema
CagriSema (Semaglutide + Cagrilintide)
weight-loss
Phase 3 Clinical Trials
clinical-trials
Detailed Comparison
| Aspect | Tirzepatide | CagriSema |
|---|---|---|
| Overview | A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Shows superior weight loss results compared to semaglutide in trials.... | A next-generation combination therapy by Novo Nordisk combining semaglutide with cagrilintide (an amylin analogue). Aims for even stronger weight loss effects than Wegovy alone.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Activates both GIP and GLP-1 receptors, providing dual hormone action. This combination may provide enhanced metabolic benefits compared to GLP-1 alon... | Dual mechanism: semaglutide activates GLP-1 receptors while cagrilintide mimics amylin, a hormone that slows gastric emptying and promotes satiety. Th... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.